Data as of .
BIB vs BIS: which held to its multiple?
Over three months against its own daily promise, BIB finished 6.6 points short and BIS 4.3 points over.
ETFIQ Decay Resistance Score: BIS scores higher
Did it keep up with its own daily multiple, compounded day by day?
A percentile among the 391 leveraged ETFs, long, over three months. It is a position in a set, not a rating, and neither end of it is a recommendation. All leveraged ETFs ranked by it · How it is computed
Performance, window by window
| Window | Total return | Multiple would give | Difference | |||
|---|---|---|---|---|---|---|
| BIB | BIS | BIB | BIS | BIB | BIS | |
| 1 month | +0.3% | −3.1% | +2.2% | −2.2% | −1.9 pts | −0.9 pts |
| 3 months | +32.8% | −28.1% | +37.9% | −37.9% | −5.0 pts | +9.7 pts |
| 6 months | +39.6% | −34.8% | +45.4% | −45.4% | −5.8 pts | +10.6 pts |
| 1 year | +86.1% | −53.5% | +83.0% | −83.0% | +3.1 pts | +29.4 pts |
| 3 years | +117.8% | −68.1% | +121.1% | −121.1% | −3.3 pts | +52.9 pts |
| Since launch | +1404.7% | −99.9% | not meaningful | not meaningful | not meaningful | not meaningful |
| BIB ProShares Ultra Nasdaq Biotechnology Aims to return twice the daily move of Nasdaq Biotechnology (IBB) | BIS ProShares UltraShort Nasdaq Biotechnology Aims to return twice the opposite of the daily move of Nasdaq Biotechnology (IBB) | |
|---|---|---|
| Issuer | ProShares | ProShares |
| Sets out to return | +2x | -2x |
| On | IBB | IBB |
| Segment | sector | sector |
| Fund returned, 3 months | +32.8% | −28.1% |
| Underlying returned, 3 months | +18.9% | +18.9% |
| What the stated multiple implies, 3 months | +37.9% | −37.9% |
| Difference from stated, 3 months | −5.0 pts | +9.7 pts |
| Fund returned, 1 year or since launch | +86.1% | −53.5% |
| Difference from stated, over that window | +3.1 pts | +29.4 pts |
| Underlying volatility | 24% | 24% |
| Expense ratio | 0.95% | 0.95% |
| Launched | Apr 8, 2010 | Apr 8, 2010 |
BIB in plain words
Three months to Sep 11, 2026: BIB returned +32.8% where its own daily promise gave +39.4%, 6.6 points short. Read the multiple against the whole window instead and +2 times IBB's 18.9% implies +37.9%, which makes BIB look 5.0 points short. 1.6 of that is daily compounding, which happens to any +2 times fund over the same path, and the rest is the fund. BIB aims to return +2 times IBB's move each day, then resets. Over one day it does that. Over longer, the daily results compound, so the total is not +2 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more. IBB moved at 24% annualized over that window. That is what decides how far the two figures separate: the same fund on a calm underlying and a violent one is a different product.
BIS in plain words
Three months to Sep 11, 2026: BIS returned −28.1% where its own daily promise gave −32.4%, 4.3 points over. Read the multiple against the whole window instead and −2 times IBB's 18.9% implies −37.9%, which makes BIS look 9.7 points over. 5.5 of that is daily compounding, which happens to any −2 times fund over the same path, and the rest is the fund. BIS aims to return -2 times IBB's move each day, then resets. Over longer, the daily results compound, so the total is not -2 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more.
Questions people ask
- Which came closer to its stated multiple, BIB or BIS?
- Over the window to Sep 11, 2026, BIB finished 5.0 points from what its multiple implies and BIS finished 9.7 points from its own, so BIB came closer. Neither figure predicts the next window: it depends on how much the underlying moves about.
- Are BIB and BIS levered on the same thing?
- Yes. Both are levered on Nasdaq Biotechnology, BIB at +2 times and BIS at -2 times the daily move.
- Which one decays faster, BIB or BIS?
- Decay follows how much the underlying moves about. Over this window BIB’s moved at 24% annualized and BIS’s at 24%, so BIB has the rougher ride and, at the same multiple, loses more to compounding.
- Can I hold BIB or BIS for a year?
- Both reset every day, so the multiple in the name applies to a single day and the daily results compound. Over a year the total is not the multiple times the year’s move, and in a market that falls and comes back it is reliably less. ETFIQ makes no recommendation either way.
- Which is cheaper, BIB or BIS?
- BIB charges 0.95% a year and BIS charges 0.95%, so BIB is cheaper. Fees come from each fund's prospectus.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BIB against BIS, data as of Sep 11, 2026. https://etfiq.com/compare/leverage/BIB-BIS Free to use with attribution; the underlying files are at Open data.